Until recently, the published studies with the new obesity pharmacotherapies have had up to 2 years follow-up [12]
Vitamins C, E, Selenium, and Glutathione - Oxidative stress (an increase in toxins, such as free radicals, and a decrease in the body's ability to detoxify or repair damages caused by these free radicals) has been shown to be elevated in individuals with ASD
Anxiolytic effects of Gly-His-Lys peptide and its analogs
The main ongoing studies: REDEFINE 1 , Phase 3 obesity without T2D (results 20242025, preliminarily 25.3 %) REDEFINE 2 , Phase 3 obesity + T2D REDEFINE 3 , Phase 3 cardiovascular outcome trial (n~7000) Stand-alone clinical development of Cagrilintide is limited , Novo Nordisk is primarily investing in the CagriSema combination
Gastrointestinal Health: Bepecin has been investigated for its potential benefits in addressing gastrointestinal disorders in horses